Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, HBM Holdings's Enterprise Value is €865.8 Mil.
HBM Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €82.6 Mil. Therefore, HBM Holdings's EV-to-EBIT ratio for today is 10.48.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, HBM Holdings's Enterprise Value is €865.8 Mil.
HBM Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €84.8 Mil. Therefore, HBM Holdings's EV-to-EBITDA ratio for today is 10.21.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, HBM Holdings's Enterprise Value is €865.8 Mil.
HBM Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €136.2 Mil. Therefore, HBM Holdings's EV-to-Revenue ratio for today is 6.36.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, HBM Holdings's Enterprise Value is €865.8 Mil.
HBM Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €60.2 Mil. Therefore, HBM Holdings's EV-to-FCF ratio for today is 14.38.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
HBM Holdings (FRA:6XY) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
HBM Holdings's current Enterprise Value is €865.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €82.6 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
HBM Holdings's current Enterprise Value is €865.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €84.8 Mil.
HBM Holdings's current Enterprise Value is €865.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €136.2 Mil.
HBM Holdings's current Enterprise Value is €865.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €70.3 Mil.
HBM Holdings's current Enterprise Value is €865.8 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. HBM Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €60.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings Enterprise Value Related Terms
HBM Holdings Enterprise Value Historical Data
* Premium members only.
The historical data trend for HBM Holdings's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XY vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, HBM Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HBM Holdings Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HBM Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where HBM Holdings's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
HBM Holdings's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HBM Holdings (FRA:6XY) has a Enterprise Value of €865.8 Mil as of Jul. 30, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on HBM Holdings and its competitors.
Is HBM Holdings' Enterprise Value too high?
HBM Holdings' current Enterprise Value is €865.8 Mil. Overall, HBM Holdings has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HBM Holdings' Enterprise Value compare to VRTX and REGN?
HBM Holdings' Enterprise Value of €865.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on HBM Holdings and its competitors. HBM Holdings's current Enterprise Value is €865.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HBM Holdings stock overvalued right now?
Based on GuruFocus' analysis, HBM Holdings (FRA:6XY) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.33 — trading 79.7% above its estimated fair value. The current Enterprise Value is €865.8 Mil. HBM Holdings' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For HBM Holdings (FRA:6XY), the current Enterprise Value is €865.8 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HBM Holdings (FRA:6XY) Overvalued in 2026?
Based on GuruFocus' analysis, HBM Holdings stock appears to be overvalued.
The current stock price of €1.33 is trading 79.7% above its estimated GF Value™ of €0.74.
GuruFocus considers HBM Holdings to be Significantly Overvalued.
Key valuation signals for FRA:6XY:
Enterprise Value: €865.8 Mil
GF Value™: €0.74 vs. price of €1.33 (79.7% above fair value)
No single metric tells the full story. See the FRA:6XY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the Europe.
64GF Score
Get the complete analysis for FRA:6XY
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XY has been successfully added to your 
